Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MDT 
Medtronic PLC (MDT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MDT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -15.14% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 113.97B USD | Price to earnings Ratio 27.09 | 1Y Target Price 97.09 |
Price to earnings Ratio 27.09 | 1Y Target Price 97.09 | ||
Volume (30-day avg) 7988780 | Beta 0.82 | 52 Weeks Range 74.13 - 95.49 | Updated Date 04/2/2025 |
52 Weeks Range 74.13 - 95.49 | Updated Date 04/2/2025 | ||
Dividends yield (FY) 3.16% | Basic EPS (TTM) 3.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.83% | Operating Margin (TTM) 21.95% |
Management Effectiveness
Return on Assets (TTM) 4.66% | Return on Equity (TTM) 8.44% |
Valuation
Trailing PE 27.09 | Forward PE 15.13 | Enterprise Value 132177274757 | Price to Sales(TTM) 3.43 |
Enterprise Value 132177274757 | Price to Sales(TTM) 3.43 | ||
Enterprise Value to Revenue 3.98 | Enterprise Value to EBITDA 15.27 | Shares Outstanding 1282540032 | Shares Floating 1280388832 |
Shares Outstanding 1282540032 | Shares Floating 1280388832 | ||
Percent Insiders 0.26 | Percent Institutions 86.04 |
Analyst Ratings
Rating 3.75 | Target Price 95.56 | Buy 5 | Strong Buy 11 |
Buy 5 | Strong Buy 11 | ||
Hold 14 | Sell 1 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Medtronic PLC
Company Overview
History and Background
Founded in 1949 in Minneapolis, Minnesota, Medtronic has grown from a small medical equipment repair shop to a global medical technology leader, pioneering therapies for a wide range of chronic diseases.
Core Business Areas
- Cardiovascular Portfolio: Includes cardiac rhythm management devices (pacemakers, defibrillators), coronary and peripheral vascular therapies (stents, balloons), and structural heart therapies (heart valves). It addresses various heart conditions and vascular diseases.
- Neuroscience Portfolio: Offers therapies for neurological disorders and spinal conditions, including neuromodulation devices (spinal cord stimulators, deep brain stimulators), neurosurgery tools, and spinal implants.
- Medical Surgical Portfolio: Focuses on minimally invasive surgery, advanced energy devices, surgical robotics, and respiratory monitoring solutions.
- Diabetes Portfolio: Provides insulin pumps, continuous glucose monitoring (CGM) systems, and integrated diabetes management solutions.
Leadership and Structure
Geoff Martha serves as Chairman and CEO. The organizational structure is based on portfolio segments, with each segment led by a president responsible for its performance and strategy. Functions include finance, legal, HR, and R&D.
Top Products and Market Share
Key Offerings
- Market Share (%): 35
- Pacemakers: Medtronic is a leading provider of pacemakers, devices that regulate heart rhythm. They hold a significant market share. Competitors include Abbott and Boston Scientific. Revenue from this product is not available, but it is significant to overall earnings.
- Insulin Pumps (MiniMed Series): Medtronic's MiniMed series is a well-known line of insulin pumps for diabetes management. Competitors include Tandem Diabetes Care and Insulet. Market share data is dynamic and competitive.
- Market Share (%): 20
- Market Share (%): 40
- Spinal Cord Stimulators (SCS): Medtronic offers SCS devices for chronic pain management. The company has a considerable share of the global market. Competitors include Boston Scientific and Abbott.
Market Dynamics
Industry Overview
The medical technology industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, technological advancements, and rising healthcare spending. Innovation and regulatory approvals are key drivers.
Positioning
Medtronic is a market leader with a broad product portfolio, strong brand recognition, and extensive global presence. Its size and diversified business provide competitive advantages. It is positioning itself with advanced technologies and new therapies.
Total Addressable Market (TAM)
The global medical devices market is expected to reach over $600 billion by 2030. Medtronic is well-positioned to capture a significant share of this TAM through its diverse portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global presence and distribution network
- Strong brand reputation
- Extensive R&D capabilities
- Leadership in key market segments
Weaknesses
- Exposure to regulatory scrutiny
- Slower organic growth in some segments
- Integration challenges from acquisitions
- Debt burden
- Complexity in innovation pipeline
Opportunities
- Expansion in emerging markets
- Development of innovative therapies and technologies
- Growth in telehealth and remote monitoring
- Strategic acquisitions and partnerships
- Increased adoption of minimally invasive procedures
Threats
- Intense competition
- Pricing pressures and healthcare cost containment
- Technological obsolescence
- Product liability litigation
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- BSX
- ABT
Competitive Landscape
Medtronic benefits from its size and diversified portfolio. However, competitors like Johnson & Johnson, Boston Scientific, and Abbott have strong positions in specific market segments. Competition is intense across all areas.
Major Acquisitions
Mazor Robotics
- Year: 2018
- Acquisition Price (USD millions): 1700
- Strategic Rationale: Enhanced Medtronic's capabilities in spinal surgery with robotic-assisted technology.
HeartWare International
- Year: 2016
- Acquisition Price (USD millions): 1100
- Strategic Rationale: HeartWare was one of the medical devices leaders and its products included HVAD system (Ventricular assist device).
Growth Trajectory and Initiatives
Historical Growth: Medtronic has grown through organic growth and acquisitions, expanding its product portfolio and geographic reach.
Future Projections: Analysts project continued growth for Medtronic, driven by new product launches and expansion in emerging markets. Revenue is expected to grow in the mid-single digits.
Recent Initiatives: Recent initiatives include investments in robotic surgery, diabetes management, and cardiovascular therapies. They also focus on digital health solutions and partnerships.
Summary
Medtronic is a strong medical technology company with a diversified portfolio and global presence. Its innovative therapies and strong brand are working well. Medtronic should watch out for increasing competition and regulatory hurdles. They should also be aware of macroeconomic conditions, as the demand for their goods can slow down during recessions.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
SYK
Stryker Corporation
SYK
Stryker Corporation
Sources and Disclaimers
Data Sources:
- Medtronic PLC Annual Reports
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Medtronic PLC
Exchange NYSE | Headquaters - | ||
IPO Launch date 1978-01-13 | Chairman of the Board & CEO Mr. Geoffrey Straub Martha | ||
Sector Healthcare | Industry Medical Devices | Full time employees 95000 | Website https://www.medtronic.com |
Full time employees 95000 | Website https://www.medtronic.com | ||
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.